KIMS Q2 FY27 consolidated revenue Rs 1,363.0 cr; PAT Rs 75.7 cr YoY
For Q2 FY27, KIMS reported consolidated total revenue of Rs 1,363.00 cr and PAT of Rs 75.70 cr versus Rs 964.90 cr and Rs 72.00 cr in Q2 FY26.
Key takeaways
- Total revenue Rs 1,363.00 cr in Q2 FY27 vs Rs 964.90 cr in Q2 FY26
- Operating revenue Rs 1,344.40 cr in Q2 FY27 vs Rs 960.70 cr a year ago
- EBITDA Rs 278.90 cr in Q2 FY27 vs Rs 208.20 cr in Q2 FY26
- PAT Rs 75.70 cr in Q2 FY27 vs Rs 72.00 cr in Q2 FY26
- Basic EPS Rs 1.81 in Q2 FY27 vs Rs 1.67 in Q2 FY26
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 1,363.00 cr | Rs 964.90 cr | +41.3% |
| PAT | Rs 75.70 cr | Rs 72.00 cr | +5.1% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 5.63% of revenue, down 186 bps from 7.49%.
• Basis: Consolidated financials, as presented in the financial highlights table under "Financial & Operational Highlights - 1/2" (statement of financial results proxy within the investor presentation).
• Periods compared: Quarter ended 30 September 2026 (Q2 FY27) versus quarter ended 30 September 2025 (Q2 FY26), as labelled in the financial highlights table.
Key P&L lines (Q2 FY27 vs Q2 FY26)
- Operating Revenue: Rs 1,344.40 cr (Q2 FY27) vs Rs 960.70 cr (Q2 FY26)
- Other Income: Rs 18.60 cr (Q2 FY27) vs Rs 4.20 cr (Q2 FY26)
- Total Revenue: Rs 1,363.00 cr (Q2 FY27) vs Rs 964.90 cr (Q2 FY26)
- EBITDA: Rs 278.90 cr (Q2 FY27) vs Rs 208.20 cr (Q2 FY26)
- PBT*: Rs 106.60 cr (Q2 FY27) vs Rs 96.80 cr (Q2 FY26)
- PAT*: Rs 75.70 cr (Q2 FY27) vs Rs 72.00 cr (Q2 FY26)
- Basic EPS: Rs 1.81 (Q2 FY27) vs Rs 1.67 (Q2 FY26)
- Diluted EPS: Rs 1.81 (Q2 FY27) vs Rs 1.67 (Q2 FY26)
*As disclosed in the financial highlights table, PBT and PAT include (Loss)/gain on fair valuation of Call option (net) of (0.30) cr in Q2 FY26 and 13.20 cr in Q2 FY27, and share of profit from associate net of tax of 0.70 cr in Q2 FY27.
According to the financial highlights section of the investor presentation (labelled "Financial & Operational Highlights - 1/2"), consolidated operating revenue for the quarter ended 30 September 2026 (Q2 FY27) was Rs 1,344.40 cr, compared with Rs 960.70 cr in the corresponding quarter a year earlier (Q2 FY26). Including other income of Rs 18.60 cr (Rs 4.20 cr in Q2 FY26), total revenue came in at Rs 1,363.00 cr versus Rs 964.90 cr a year ago.
EBITDA for Q2 FY27 is reported at Rs 278.90 cr, up from Rs 208.20 cr in Q2 FY26, as per the same table. The company also discloses EBITDA (%) on Total Revenue of 20.5% for Q2 FY27 and 21.6% for Q2 FY26 in that table, but only the absolute EBITDA figures are used here.
Profit before tax (PBT), which the company notes includes the impact of fair valuation of a call option and share of profit from an associate, stood at Rs 106.60 cr for Q2 FY27, compared with Rs 96.80 cr in Q2 FY26. Profit after tax (PAT), on the same basis, was Rs 75.70 cr for Q2 FY27 versus Rs 72.00 cr in Q2 FY26, as disclosed in the financial highlights.
Basic and diluted earnings per share (EPS) for Q2 FY27 are both reported at Rs 1.81, compared with Rs 1.67 for Q2 FY26. These EPS figures are taken directly from the financial highlights table in the investor presentation, which summarises the statement of financial results for the quarter.
Track Krishna Institute of Medical Sciences Ltd
Cruxal reads every Krishna Institute of Medical Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
